Skip to search formSkip to main contentSkip to account menu

gefitinib

Known as: 4-(3Chloro-4-flurophenylamine)-7-methoxy-6(3-(4morpholinyl)quinazoline, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) propoxy]-4-quinazolinamine, gefitinib [Chemical/Ingredient] 
An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal… 
National Institutes of Health

Related topics

Related topics

17 relations

Broader (3)

Antineoplastic AgentsProtein Kinase InhibitorsQuinazolines
Drug AllergyEGFR protein, humanHER1 Antagonists [MoA]Lung Neoplasms

Narrower (2)

IressaZD 1839

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian…
Highly Cited
2014
Highly Cited
2014
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
2014
2014
Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line
Previous studies have observed that Paris saponin I (PSI) exerts a wide range of pharmacological activities, including cytotoxic… 
Highly Cited
2011
Highly Cited
2011
Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Review
2008
Review
2008
Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers (NSCLC) and is a… 
Highly Cited
2007
Highly Cited
2007
A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response
Purpose: At presentation, most cases of adenocarcinoma of the esophagus (ACE) are inoperable. Although chemotherapy can prolong… 
Highly Cited
2007
Highly Cited
2007
Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.
Highly Cited
2005
Highly Cited
2005
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
Gefitinib (IRESSA), an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, has antitumour activity in the… 
Highly Cited
2004
Highly Cited
2004
Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
Purpose: A worldwide compassionate-use program has enabled >42,000 patients with advanced non-small cell lung cancer (NSCLC) to… 
Highly Cited
1997
Highly Cited
1997
Modulation of glutamate release by a nitric oxide/cyclic GMP-dependent pathway.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)